Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by 87c; Guides

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q4 EPS of $3.48, $0.87 better than the analyst estimate of $2.61. Revenue for the quarter came in at $251.7 million versus the consensus estimate of $191.1 million.

GUIDANCE:

Fulgent Genetics, Inc. sees Q1 2022 revenue of ~$245 million, versus the consensus of $197.55 million.

Fulgent Genetics, Inc. sees FY2022 revenue of ~$600 million, versus the consensus of $587.87 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Morgan Stanley Resumes Victoria Secret (VSXY) at Overweight
• Intercontinental Exchange (ICE) PT Lowered to $208 at Raymond James, 'we view the risk/reward as attractive'